Sterling Capital Management LLC Increases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Sterling Capital Management LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 51.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,099 shares of the medical equipment provider's stock after purchasing an additional 4,779 shares during the period. Sterling Capital Management LLC's holdings in Hologic were worth $1,016,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of HOLX. General Partner Inc. bought a new stake in shares of Hologic in the 4th quarter valued at about $26,000. Venturi Wealth Management LLC grew its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares during the last quarter. Finally, Smithfield Trust Co raised its position in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

Hologic stock traded down $1.02 during midday trading on Monday, reaching $56.54. The company had a trading volume of 181,339 shares, compared to its average volume of 2,743,448. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The firm's fifty day simple moving average is $61.58 and its 200-day simple moving average is $70.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $12.69 billion, a P/E ratio of 17.84, a P/E/G ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research analyst reports. Royal Bank of Canada decreased their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Argus cut Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.